Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Macular Edema and Macular Degeneration Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market for macular edema and macular degeneration has experienced robust expansion recently, demonstrating a projected increase from $10.33 billion in 2025 to $11.03 billion in 2026, reflecting a compound annual growth rate of 6.8%. Factors contributing to this growth during the past period include the rising incidence of diabetes and various retinal conditions, an aging demographic with an elevated susceptibility to vision impairment, the positive clinical outcomes associated with anti-VEGF injections, heightened public consciousness regarding macular diseases, and the broader establishment of ophthalmology clinics.

The marketplace for conditions affecting the macula, specifically macular edema and macular degeneration, is poised for considerable expansion, projected to reach a valuation of $14.33 billion by 2030, reflecting a compound annual growth rate of 6.8%. This upward trajectory through the forecast period is fueled by several key factors, including an increasing worldwide prevalence of diabetes, heightened efforts in screening for retinal pathologies, a surge in the preference for less invasive ocular treatments, broader availability of sophisticated ophthalmological services, and increased financial investment in safeguarding vision. Key developments anticipated during this timeframe encompass a greater uptake of treatments employing anti-VEGF agents, a growing emphasis on prompt identification and management of these eye conditions, expanded utilization of combined therapeutic approaches involving medication and laser treatments, a heightened focus on addressing diabetes-related eye issues, and the growth of eye care services provided in outpatient settings and clinics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

Macular Edema and Macular Degeneration Market Development Factors: Which Trends Are Supporting Demand?

The increasing prevalence of diabetes is anticipated to fuel the expansion of the marketplace for macular edema and macular degeneration. Diabetes, a persistent health affliction defined by elevated blood sugar, inflicts damage upon the eye’s vascular network, potentially leading to these specific retinal conditions. Illustrating this trend, The National Health Service (NHS England) reported in June 2024 that the count of individuals diagnosed with pre-diabetes within England escalated to 3,615,330 in 2023, an 18% jump from the previous year’s figure of 3,065,825. Notably, the number of cases among individuals under forty years old saw a significant surge of almost 25%, climbing from 173,166 in 2022 to 216,440 in 2023. Consequently, this growing diabetic population directly contributes to the upward trajectory of the macular edema and macular degeneration market.

Macular Edema and Macular Degeneration Market Segmentation Trends And Revenue Drivers

The macular edema and macular degeneration market covered in this report is segmented –

1) By Treatment Type: Drug Therapy, Laser Treatment

2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Combination Therapy (Anti-VEGF + Steroids)

2) By Laser Treatment: Focal Laser Photocoagulation, Subthreshold Laser Therapy, MicroPulse Laser Therapy

Macular Edema and Macular Degeneration Market Transformation Trends: Which Innovations Are Driving Change?

Leading corporations within the macular edema and macular degeneration market are concentrating their efforts on pioneering novel solutions, including self-replenishing ocular implants engineered to alleviate treatment challenges, foster better patient compliance, and achieve more stable long-term therapeutic efficacy. These implantable ocular devices, designed for ongoing drug release, are compact, refillable units surgically inserted into the eye that gradually administer medication over extended periods, thereby lessening the frequency of necessary injections and ensuring consistent, enduring treatment for conditions affecting the retina. As an illustration, in February 2025, the FDA granted approval to Susvimo, a product from Swiss biotech firm F. Hoffmann-La Roche Ltd, which is a refillable ocular implant containing the anti-VEGF agent ranibizumab for managing diabetic macular edema (DME). Susvimo functions as an enduring, implanted reservoir capable of continuously dispensing a specially formulated version of ranibizumab, thereby sustaining effective drug concentrations for prolonged intervals. In contrast to conventional anti-VEGF intravitreal injections, which generally necessitate monthly or bimonthly administration, Susvimo provides a replenishment interval of approximately six months, significantly easing the treatment load for patients. Its continuous release mechanism improves patient adherence, simplifies clinical processes, and delivers sustained anatomical and visual improvements for individuals with persistent retinal conditions.

Macular Edema and Macular Degeneration Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the macular edema and macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co Ltd, Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Kodiak Sciences Inc., Opthea Limited, IVERIC bio Inc., Neurotech Pharmaceuticals Inc., Regenxbio Inc., Graybug Vision Inc., Clearside Biomedical Inc., Kubota Pharmaceutical Holdings Co Ltd, Acucela Inc., PanOptica Inc., Ocugen Inc.

Access The Complete Macular Edema and Macular Degeneration Market Report:

https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

Macular Edema and Macular Degeneration Market Regional Outlook: Where Are The Largest Opportunities Located?

North Americawas the largest region in the macular edema and macular degeneration market in 2025. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model